Literature DB >> 18955962

Current state of immunotherapy for Alzheimer's disease.

Norman R Relkin1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18955962     DOI： 10.1017/s1092852900027061

Source DB:  PubMed          Journal:  CNS Spectr        ISSN： 1092-8529            Impact factor:   3.790


× No keyword cloud information.
  5 in total

1.  Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial.

Authors:  Richard Dodel; Axel Rominger; Peter Bartenstein; Frederik Barkhof; Kaj Blennow; Stefan Förster; Yaroslav Winter; Jan-Philipp Bach; Julius Popp; Judith Alferink; Jens Wiltfang; Katharina Buerger; Markus Otto; Piero Antuono; Michael Jacoby; Ralph Richter; James Stevens; Isaac Melamed; Jerome Goldstein; Stefan Haag; Stefan Wietek; Martin Farlow; Frank Jessen
Journal:  Lancet Neurol       Date:  2013-01-31       Impact factor: 44.182

Review 2.  Alzheimer's disease biomarker discovery in symptomatic and asymptomatic patients: experimental approaches and future clinical applications.

Authors:  Lap Ho; Hayley Fivecoat; Jun Wang; Giulio Maria Pasinetti
Journal:  Exp Gerontol       Date:  2009-09-29       Impact factor: 4.032

3.  Alzheimer's disease therapeutic research: the path forward.

Authors:  Paul S Aisen
Journal:  Alzheimers Res Ther       Date:  2009-07-09       Impact factor: 6.982

Review 4.  Novel strategies for the prevention of dementia from Alzheimer's disease.

Authors:  Diana W Shineman; Howard M Fillit
Journal:  Dialogues Clin Neurosci       Date:  2009       Impact factor: 5.986

Review 5.  Recent developments in Alzheimer's disease therapeutics.

Authors:  Michael S Rafii; Paul S Aisen
Journal:  BMC Med       Date:  2009-02-19       Impact factor: 8.775
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.